Comparative Pharmacology
Head-to-head clinical analysis: NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC versus U GENCIN.
Head-to-head clinical analysis: NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC versus U GENCIN.
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC vs U-GENCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Neomycin is an aminoglycoside that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibition of protein synthesis. Polymyxin B is a polypeptide that disrupts bacterial cell membrane permeability by interacting with phospholipids. Bacitracin inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the lipid carrier in peptidoglycan biosynthesis.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting bacterial protein synthesis.
Apply thin layer to affected area 2-3 times daily. For ophthalmic use: 1-2 drops in affected eye every 4 hours, or 1/2 inch ribbon of ointment in conjunctival sac 2-3 times daily.
1-2 mg/kg IV every 8 hours for 7-10 days, targeting peak serum concentration of 6-10 mcg/mL and trough <2 mcg/mL.
None Documented
None Documented
Neomycin: 2-3 h (terminal), prolonged in renal impairment; polymyxin B: 6-7 h (terminal), extended in renal failure; bacitracin: 1.5 h (if absorbed), not clinically relevant due to minimal absorption.
Terminal elimination half-life is 2-3 hours in patients with normal renal function; may prolong to 20-40 hours in end-stage renal disease
Renal: ~90% of absorbed neomycin and polymyxin B; bacitracin zinc: minimal systemic absorption, excreted primarily in feces. For neomycin: ~99% fecal after oral; polymyxin B: ~60% renal, rest biliary; bacitracin: nearly 100% renal if absorbed.
Primarily renal (glomerular filtration) with 40-70% excreted unchanged in urine within 24 hours; minor biliary/fecal (<5%)
Category A/B
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic